ZR2 Bioenergy Ltd (ZR2) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by ZR2 Bioenergy Ltd on NSE and BSE, with an AI summary of each filing.
This is to inform that the Board of Directors, at its meeting held today i.e. Friday, August 14, 2026 inter-alia have considered and approved the following: 1. Un-audited Financial Results ....
Financial Result · 15 Aug 2026, 4:05 am
ZR2 Bioenergy Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 0.0 ■ EBITDA: -16.7 (-20.1% YoY | +21.1% QoQ) ■ EBITDA Margin (%): 0.0 ■ PAT: 22.0 (-27.9% YoY | +10.7% QoQ) ■ EPS (INR): 0.14 (+100.0% YoY | +16.7% QoQ)
BOARD MEETING OUTCOME FOR APPROVING AND CONSIDERATION OF THE UNAUDITED FINANCIAL YEAR ENDED 30TH JUNE 2026.
Others (Uncategorized) · 15 Aug 2026, 3:59 am
ZR2 Bioenergy Q1FY27 Results Approved ZR2 Bioenergy reported Q1FY27 consolidated results for the quarter ended 30 Jun'26. Revenue from operations was ₹41.63 lakhs and total income stood at ₹41.63 lakhs. Profit After Tax (PAT) was ₹22.01 lakhs, down 28% YoY from ₹30.54 lakhs but up 11% QoQ from ₹19.89 lakhs. Basic EPS for the quarter was ₹0.62. The company is transitioning into bioenergy and agri-commodities, anchored by an ethanol plant acquisition, with related agreements in advanced stages. The auditors issued an unqualified limited review report.
Pursuant to Regulation 32 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Regulation ....
Others (Uncategorized) · 15 Aug 2026, 3:45 am
ZR2 Bioenergy: Issue Proceeds Halved, Unutilized Funds Deployed in Non-Standard Deposit ZR2 Bioenergy's total preferential issue proceeds were revised down from ₹248.77 crore to ₹122.40 crore following the forfeiture of warrant subscriptions. For the quarter ended 30 Jun'26, there was nil utilization towards key projects like biorefinery acquisition. Crisil's monitoring report flagged the deployment of ₹18.50 crore of unutilized funds in a short-term deposit with a non-deposit-taking NBFC, a deviation from standard practice. This deployment, earning 9.00% p.a., has been extended to 30 Sep'26, raising concerns about fund availability for stated objectives.
This is to inform that the Board of Directors, at its meeting held today i.e. Friday, May 29, 2026 inter-alia have considered and approved the following: 1. Audited Financial Results (Standalone ....
Financial Result · 30 May 2026, 12:25 am
ZR2 Bioenergy Reports Q4'26 and FY26 Standalone Audited Results ZR2 Bioenergy reported standalone results for the quarter and year ended Mar 31, '26. Q4'26 profit after tax stood at ₹20.28 lakhs, a decrease from ₹23.02 lakhs in Q3'26 but up from ₹10.51 lakhs in Q4'25. For FY26, net profit was ₹70.48 lakhs, a significant increase from ₹8.22 lakhs in FY25. Basic EPS for FY26 was ₹1.97 versus ₹0.23 in the prior year. The company forfeited 2.59 crore warrants on Feb 14, '26, recognizing ₹4,212.33 lakhs from forfeited application money.
This is to inform that the Board of Directors, at its meeting held today i.e. Friday, May 29, 2026 inter-alia have considered and approved the following: 1. Audited Financial Results (Standalone ....
Outcome · 30 May 2026, 12:10 am
ZR2 Bioenergy Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakhs) ■ Revenue: 0.0 ■ EBITDA: -21.1 (-5.7% YoY | -200.6% QoQ) ■ EBITDA Margin (%): 0.0 ■ PAT: 19.9 (+75.9% YoY | -13.1% QoQ) ■ EPS (INR): 0.12 (+300.0% YoY | +140.0% QoQ)
The Exchange has sought clarification from ZR2 Bioenergy Limited with reference to significant movement in price, in order to ensure that investors have latest relevant information about ....
Others (Uncategorized) · 28 May 2026, 11:08 pm
ZR2 Bioenergy Attributes Significant Share Price Movement to Market Factors In a clarification dated 28th May'26 to the BSE regarding significant share price movement, ZR2 Bioenergy Limited (Scrip Code: 506640) stated there is no undisclosed pending material information, event, or announcement that could impact the price. The company believes the recent price volatility is purely market-driven and a result of market conditions. Management reiterated its commitment to compliance with all SEBI disclosure regulations. This response was prompted by a query from the exchange seeking to safeguard investor interests.
The Exchange has sought clarification from ZR2 Bioenergy Limited with reference to significant movement in price, in order to ensure that investors have latest relevant information about ....
Others (Uncategorized) · 28 May 2026, 11:03 pm
ZR2 Bioenergy Attributes Share Price Surge to Market Factors In a clarification dated 28th May'26 to the BSE regarding significant share price movement, ZR2 Bioenergy (Scrip: 506640) confirmed it has no undisclosed material information or pending announcements that could impact the price. The company stated that the recent price volatility is purely market-driven and a result of market conditions. Management reaffirmed its commitment to timely disclosures in compliance with SEBI regulations, asserting that all relevant information has been shared with the exchanges.
ZR2 Bioenergy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve In compliance with Regulation ....
Intimation · 29 May 2026, 5:30 am
ZR2 Bioenergy Board Meeting for Q4 FY26 Results on May 29, 2026 ZR2 Bioenergy (BSE: 506640) has scheduled its Board of Directors meeting for Fri, 29 May'26. The agenda includes the consideration and approval of both standalone and consolidated audited financial results for the quarter and financial year ended Mar 31, 2026. In accordance with insider trading regulations, the trading window for company securities has been closed since Apr 1, 2026, and will reopen 48 hours after the results are declared.
MONITORING AGENCY REPORT FOR THE QUARTER ENDED 31ST MARCH, 2026
Others (Uncategorized) · 16 May 2026, 3:15 am
ZR2 Bioenergy Q4FY26: Issue Proceeds Revised Down, Unutilized Funds Deployed with NBFC ZR2 Bioenergy's preferential issue proceeds were revised down from Rs 248.77 crore to Rs 122.40 crore due to forfeiture of warrant subscriptions. As of 31 Mar'26, Rs 103.90 crore was utilized, leaving Rs 18.50 crore unutilized. These funds are in a short-term deposit with NBFC Sukhmehar Finance Pvt Ltd, maturing 30 Jun'26, which monitoring agency Crisil highlighted as a deviation from standard practice. The forfeiture has also impacted the viability of the issue's objectives, specifically delaying the General Corporate Purposes fund utilization.
The Exchange has sought clarification from ZR2 Bioenergy Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....
Others (Uncategorized) · 09 Apr 2026, 12:39 am
The Exchange has sought clarification from ZR2 Bioenergy Ltd on March 17, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....
Others (Uncategorized) · 18 Mar 2026, 12:33 am
This is in furtherance of the intimation given by the Company on May 10, 2024, wherein we had informed you that the Company had allotted 2,59,22,000 convertible warrants of the Company ....
Others (Uncategorized) · 19 Feb 2026, 11:03 pm
ZR2 Bioenergy Forfeits Rs. 42.12cr as Warrant Holders Decline Conversion ZR2 Bioenergy (formerly Gujchem Distillers) has forfeited Rs. 42.12 crore received as an initial subscription amount for 2,59,22,000 convertible warrants. The warrants, originally allotted on a preferential basis on 10 May'24 at Rs. 65 each, were not converted into equity shares by the holders within the stipulated 18-month period ending 13 Feb'26. The forfeited amount represents the 25% upfront payment made by the proposed promoter and strategic investors. This action is taken per SEBI regulations, impacting the company's previously planned capital infusion.
Allotment of 1,23,50,000 Additional Equity Shares (on account of conversion of Compulsorily Convertible Debentures ('CCDs') into equity shares.
Others (Uncategorized) · 19 Feb 2026, 10:56 pm
ZR2 Bioenergy Allots 1.23 Crore Shares on CCD Conversion ZR2 Bioenergy Ltd allotted 1,23,50,000 new equity shares on 14 Feb'26 upon the conversion of Compulsorily Convertible Debentures (CCDs). The shares, with a face value of Re. 1, were converted at an issue price of Rs. 65 per share, aggregating to Rs. 80.28 crore. The allotment was made to ZR2 Group Holdings Limited, a promoter group entity. Following the conversion, ZR2 Group Holdings' stake in the company increased from 61% to 91.26%. The company will seek listing approval for these new shares.
Monitoring Agency Report for the quarter ended December 31, 2025 in respect of Funds raised by issuance of Convertible Warrants and Compulsory Convertible Debentures on a Preferential Basis
Others (Uncategorized) · 17 Feb 2026, 9:56 pm
ZR2 Bioenergy: Crisil Flags Deployment of Preferential Issue Proceeds ZR2 Bioenergy filed its monitoring agency report for the quarter ended 31 Dec'25, regarding its Rs 248.77 crore preferential issue. Crisil highlighted that Rs 18.50 crore of unutilized proceeds were deployed in a short-term deposit with an NBFC, Sukhmehar Finance, deviating from standard practice of using low-risk instruments. No funds were utilized during the quarter. Of the total issue size, Rs 122.40 crore has been received, with Rs 144.87 crore remaining unutilized. The NBFC deposit maturity has been extended to 30 Jun'26.
Outcome of Board Meeting held on February 14, 2026 and Submission of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2025 as per SEBI (Listing ....
Financial Result · 17 Feb 2026, 9:53 pm
ZR2 Bioenergy Limited - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakhs) ■ Revenue: 41.6 (+1196.9% YoY | -24.2% QoQ) ■ EBITDA: 34.6 (Loss to Profit YoY | +19.9% QoQ) ■ EBITDA Margin (%): 83.1 (Loss to Profit YoY | +3059 bps QoQ) ■ PAT: 22.9 (Loss to Profit YoY | -15.6% QoQ) ■ EPS (INR): 0.05 (Loss to Profit YoY | -16.7% QoQ)
Outcome of Board Meeting held on February 14, 2026 and Submission of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2025 as per SEBI (Listing ....
Others (Uncategorized) · 17 Feb 2026, 9:45 pm
ZR2 Bioenergy Reports Q3 FY26 Unaudited Financial Results ZR2 Bioenergy reported standalone results for the quarter ended 31 Dec'25, with revenue at ₹41.63 lakhs versus ₹51.95 lakhs QoQ. Net profit stood at ₹23.02 lakhs, down from ₹27.08 lakhs in the prior quarter but reversing a loss of ₹26.35 lakhs YoY. Consolidated net profit for Q3 FY26 was ₹22.88 lakhs against a net loss of ₹26.35 lakhs in Q3 FY25. The Board approved the unaudited standalone and consolidated results on 14 Feb'26. Basic standalone EPS was ₹0.65.
Resignation of Company Secretary & Compliance Officer
Change in Management · 29 Dec 2025, 3:39 pm
ZR2 Bioenergy Company Secretary Resigns Citing Compliance and Governance Issues ZR2 Bioenergy (BSE: 506640) announced the immediate resignation of its Company Secretary & Compliance Officer, Ms. Shital Gurav, effective 29th Dec'25. In her resignation letter, Ms. Gurav cited "certain compliance irregularities and gaps" that remained unaddressed despite being raised. She stated her inability to discharge duties in alignment with the mandatory compliance framework due to the prevailing circumstances, prompting her to step down to maintain professional integrity. The company cited "Governance & Other related matters" as the official reason for the change.
Monitoring Agency Report for the quarter ended September 30, 2025
Others (Uncategorized) · 15 Nov 2025, 3:21 am
Publication of Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2025 along with Limited Review Report thereon
Financial Result · 15 Nov 2025, 3:16 am
Outcome of the Board Meeting held on November 14, 2025 to consider and approve un audited (Standalone and Consolidated) Financials of the Company for the quarter and half year ended September ....
Outcome · 15 Nov 2025, 3:07 am
ZR2 Bioenergy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve unaudited (standalone and consolidated) ....
Intimation · 14 Nov 2025, 5:30 am
Appointment of Secretarial Auditor
Change in Management · 01 Oct 2025, 12:12 am
Scrutinizer''s Report on voting at the 86th Annual General Meeting of the Company held on September 29, 2025
Annual General Meeting · 01 Oct 2025, 12:03 am
Proceeding of 86th Annual General Meeting of the Company held on September 29, 2025
Annual General Meeting · 29 Sept 2025, 11:27 pm
Communication to Shareholders- Intimation on Tax Deduction on Dividend
Dividend · 12 Sept 2025, 3:24 am